文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV-1感染者中GS-6207体外耐药相关衣壳替换的频率

Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

本研究对1500例未治疗或经治HIV感染者血浆样本进行测序,检测体外筛选出的7个GS-6207耐药相关衣壳突变(L56I、M66I、Q67H、K70N、N74D、N74S、T107N)。结果显示,无论HIV亚型或治疗史,均未检出这7个突变,提示既往PI治疗失败或PI耐药突变出现预计不影响GS-6207活性。

要点

  • 在1500例HIV感染者中未检出7个GS-6207体外耐药相关衣壳突变。
  • 无论HIV亚型或治疗史(包括PI经治),均未发现这些突变。
  • 既往PI失败或PI耐药突变出现预计不影响GS-6207活性。

核心结论

  • 在1500例未治疗或经治HIV感染者中,未检出7个GS-6207体外耐药相关衣壳突变,提示既往PI失败或PI耐药突变出现预计不影响GS-6207活性。

研究设计与样本

  • 对1500例未治疗或经治(包括PI经治)HIV感染者血浆样本进行测序,分析7个GS-6207体外耐药相关衣壳突变(L56I、M66I、Q67H、K70N、N74D、N74S、T107N)的流行率。

主要发现

  • 在1500例患者样本中,无论HIV亚型或治疗史,均未检出7个GS-6207体外耐药相关衣壳突变中的任何一个。

关键数值与推荐

  • 检测的7个GS-6207体外耐药相关衣壳突变为L56I、M66I、Q67H、K70N、N74D、N74S和T107N。
  • 研究样本来自1500例未治疗或经治(包括PI经治)HIV感染者。

临床怎么用

  • 对于未治疗或经治(包括PI经治)HIV感染者,预计GS-6207的活性不受这些衣壳突变影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GS-6207 is a first-in-class HIV capsid inhibitor, targeting several functions of the HIV capsid in the viral cycle, including viral particle assembly, capsid formation and nuclear entry. GS-6207 has demonstrated picomolar potency in vitro, activity confirmed by high potency in a Phase 1 clinical study, with a long-acting antiretroviral profile with potential dosing every 6 months. In vitro resistance selections previously conducted with increasing doses of GS-6207 have identified capsid variants with reduced susceptibility to GS-6207. OBJECTIVES: To study the prevalence of capsid mutations associated with in vitro resistance to GS-6207 in people living with HIV (PLWH). METHODS: Plasma samples from ART-naive or -experienced PLWH, including PI-experienced people, were sequenced and analysed for the presence of capsid variants identified during in vitro resistance selection: L56I, M66I, Q67H, K70N, N74D, N74S and T107N. RESULTS: Among the samples from the 1500 patients studied, none of the seven GS-6207 resistance mutations identified during in vitro selection experiments was detected, regardless of HIV subtype or PLWH treatment history. CONCLUSIONS: Out of the seven HIV capsid substitutions previously selected in vitro and shown to confer phenotypic resistance to GS-6207, none of these seven mutations was observed in this large dataset, suggesting that neither PLWH with previous PI failure nor PLWH with emergence of PI resistance mutations are anticipated to impact GS-6207 activity in these diverse HIV-infected populations.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Marcelin AG, Charpentier C, Jary A, et al. Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients. J Antimicrob Chemother. 2020. PMID: 32154864. doi:10.1093/jac/dkaa060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。